Chugai Pharmaceutical Co Ltd
TSE:4519

Watchlist Manager
Chugai Pharmaceutical Co Ltd Logo
Chugai Pharmaceutical Co Ltd
TSE:4519
Watchlist
Price: 6 585 JPY -2.99% Market Closed
Market Cap: 11.1T JPY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Chugai Pharmaceutical Co Ltd stock under the Base Case scenario is 3 998.9 JPY. Compared to the current market price of 6 585 JPY, Chugai Pharmaceutical Co Ltd is Overvalued by 39%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3 998.9 JPY
Overvaluation 39%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

9.3
P/S
P/S
Price to Sales
9.3
vs History
23
vs Industry
14
Median 3Y
6
Median 5Y
8
Industry
2.4
Forward
8.9
More Details
28
P/E
P/E
Price to Earnings
28
vs History
39
vs Industry
15
Median 3Y
22.2
Median 5Y
27
Industry
20.8
Forward
24.9
More Details
33.1
P/OCF
P/OCF
Price to OCF
33.1
vs History
25
vs Industry
12
Median 3Y
22.4
Median 5Y
27.5
Industry
15.4
More Details
42.2
P/FCFE
P/FCFE
Price to FCFE
42.2
vs History
31
vs Industry
12
Median 3Y
31.2
Median 5Y
39.7
Industry
22.8
More Details
6.2
P/B
P/B
Price to Book Value
6.2
vs History
36
vs Industry
10
Median 3Y
5
Median 5Y
6
Industry
2
More Details
8.6
EV/S
EV/S
Enterprise Value to Sales
8.6
vs History
25
vs Industry
14
Median 3Y
5.5
Median 5Y
7.7
Industry
2.5
Forward
8.3
More Details
12.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
12.1
vs History
33
vs Industry
16
Median 3Y
9.2
Median 5Y
12.1
Industry
4.9
More Details
18.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
18.5
vs History
41
vs Industry
18
Median 3Y
14.3
Median 5Y
18.1
Industry
12.7
Forward
16.5
More Details
18.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
18.5
vs History
41
vs Industry
22
Median 3Y
14.3
Median 5Y
18.7
Industry
15.8
More Details
30.6
EV/OCF
EV/OCF
Enterprise Value to OCF
30.6
vs History
25
vs Industry
13
Median 3Y
20.7
Median 5Y
25.7
Industry
14
More Details
37.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
37.9
vs History
31
vs Industry
13
Median 3Y
28.8
Median 5Y
35.1
Industry
18.3
More Details
8.6
EV/IC
EV/IC
Enterprise Value to IC
8.6
vs History
23
vs Industry
9
Median 3Y
6.1
Median 5Y
7.5
Industry
1.7
More Details

Multiples Across Competitors

Competitors Multiples
Chugai Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
10.8T JPY 9.3 28 18.5 18.5
US
Eli Lilly and Co
NYSE:LLY
775.3B USD 17.2 73.2 42.6 47
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
373.9B USD 4.2 26.6 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 7.1 20.5 13.5 15.4
CH
Roche Holding AG
SIX:ROG
228.6B CHF 3.9 19.9 11.1 13.2
UK
AstraZeneca PLC
LSE:AZN
174.1B GBP 4.2 32.3 127.9 195.3
CH
Novartis AG
SIX:NOVN
196B CHF 4.3 18.7 11.3 14.5
US
Merck & Co Inc
NYSE:MRK
219.3B USD 3.4 12.8 8.7 10.2
IE
Endo International PLC
LSE:0Y5F
167.6B USD 72.3 -57.3 267.5 670.8
US
Pfizer Inc
NYSE:PFE
140B USD 2.2 17.4 8.4 12
P/E Multiple
Earnings Growth PEG
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
Average P/E: 27.7
28
9%
3.1
US
Eli Lilly and Co
NYSE:LLY
73.2
49%
1.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.6
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
20.5
19%
1.1
CH
Roche Holding AG
SIX:ROG
19.9
16%
1.2
UK
AstraZeneca PLC
LSE:AZN
32.3
36%
0.9
CH
Novartis AG
SIX:NOVN
18.7
16%
1.2
US
Merck & Co Inc
NYSE:MRK
12.8
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -57.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.4
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
Average EV/EBITDA: 397.1
18.5
9%
2.1
US
Eli Lilly and Co
NYSE:LLY
42.6
30%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.5
15%
0.9
CH
Roche Holding AG
SIX:ROG
11.1
8%
1.4
UK
AstraZeneca PLC
LSE:AZN
127.9
9%
14.2
CH
Novartis AG
SIX:NOVN
11.3
5%
2.3
US
Merck & Co Inc
NYSE:MRK
8.7
9%
1
IE
E
Endo International PLC
LSE:0Y5F
267.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
8.4
3%
2.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
JP
Chugai Pharmaceutical Co Ltd
TSE:4519
Average EV/EBIT: 1 701.4
18.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47
33%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
12%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
16%
1
CH
Roche Holding AG
SIX:ROG
13.2
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
195.3
21%
9.3
CH
Novartis AG
SIX:NOVN
14.5
8%
1.8
US
Merck & Co Inc
NYSE:MRK
10.2
12%
0.9
IE
E
Endo International PLC
LSE:0Y5F
670.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
12
10%
1.2

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 243,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.